Merck KGaA

XTRA:MRK 株式レポート

時価総額：€60.7b

Merck KGaA 将来の成長

Future 基準チェック /16

Merck KGaA利益と収益がそれぞれ年間11.6%と5.1%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に12.7% 11.6%なると予測されています。

主要情報

11.6%

収益成長率

11.61%

EPS成長率

Pharmaceuticals 収益成長24.6%
収益成長率5.1%
将来の株主資本利益率12.73%
アナリストカバレッジ

Good

最終更新日11 Aug 2026

今後の成長に関する最新情報

Recent updates

ナラティブ更新 • Aug 03

MRK: AI Partnerships And Bio-Techne Deal Will Shape Balanced Future Prospects

Analysts have raised their price target for Merck KGaA to €170 from €160, citing slightly higher assumed revenue growth, a modestly higher future P/E of about 22.4, and some pressure on projected profit margins following the agreed cash acquisition of Bio-Techne at €73 per share equivalent. Analyst Commentary Recent research on Merck KGaA is mixed, with analysts weighing the agreed Bio-Techne acquisition price of $73 per share against the company’s longer term growth drivers and current valuation levels.
ナラティブ更新 • Jul 20

MRK: Rich Bio Techne Deal And Downgrades Will Restrain Future Returns

Merck KGaA's fair value estimate has been adjusted from €112.00 to €121.00 as analysts factor in updated assumptions on revenue growth, profit margins and discount rates, alongside mixed reactions to the planned Bio Techne acquisition and its potential to support returns only under more optimistic scenarios. Analyst Commentary Recent research on Merck KGaA highlights a shift toward more cautious views, especially around the planned acquisition of Bio Techne and how it could affect valuation, execution risk, and the company’s long term growth profile.
ナラティブ更新 • Jul 06

MRK: Bio-Techne Deal And Life Science Recovery Will Drive Future Upside

Analysts have raised their fair value estimate for Merck KGaA from about €172 to roughly €177. This reflects higher blended price targets, even as they note that the planned Bio-Techne acquisition could justify the richer implied future P/E only in more optimistic scenarios.
ナラティブ更新 • Jun 22

MRK: Life Science Tools Recovery Will Support Future Upside Potential

Analysts recently adjusted their views on Merck KGaA after Street price targets diverged, including a cut to €129 at one firm that now sees a more balanced risk and reward, and a raise to €160 at another firm citing early signs of recovery in life science tools. Analyst Commentary Recent commentary on Merck KGaA reflects a split view, with some bullish analysts highlighting early signs of improvement in key segments such as life science tools, while others see the current share price as broadly aligned with the company's exposure to structural growth drivers.
ナラティブ更新 • Jun 06

MRK: Life Science Tools Recovery And Lower AI Risk Will Support Upside

Merck KGaA's updated analyst price target now centers around €160, up from €135, with analysts pointing to cautious optimism around life science tools, a more balanced risk and return profile, and sector wide reassessments of recovery potential and valuation. Analyst Commentary Recent research points to a mixed but generally firming stance on Merck KGaA.
ナラティブ更新 • May 23

MRK: Healthcare Resilience And Raised 2026 Guidance Will Support Future Upside

Narrative Update on Merck KGaA Analysts now see fair value for Merck KGaA at about €143, up from roughly €141, reflecting recent price target revisions and views that healthcare could appeal to investors given the current macro backdrop, geopolitical risks, and perceived lower exposure to AI disruption risks. Analyst Commentary Recent research snapshots show a mixed stance on Merck KGaA, with some analysts trimming price targets and others taking a more neutral starting point.
ナラティブ更新 • Apr 30

MRK: Healthcare Resilience And Sustainable Solvents Will Support Future Upside

The updated analyst price target for Merck KGaA moves modestly lower to about €141 from around €143, reflecting recent target cuts from firms citing a cautious macro backdrop and sector specific views, while still recognizing potential interest in healthcare as investors weigh geopolitical risk and AI related disruption. Analyst Commentary Recent research on Merck KGaA has focused on recalibrating expectations, with multiple firms trimming price targets and one major house initiating coverage with a neutral stance.
ナラティブ更新 • Apr 15

MRK: Reset Expectations And 2026 Guidance Will Shape Future Return Balance

Analysts have trimmed the fair value estimate for Merck KGaA from €127.00 to €112.00, reflecting recent reductions in Street price targets and a more cautious stance on profitability, despite slightly higher modeled revenue growth. Analyst Commentary Recent Street research on Merck KGaA has tilted more cautious, with several bearish analysts cutting price targets and reassessing the risk and reward balance.
ナラティブ更新 • Apr 01

MRK: Lower AI Disruption Risk And Margin Resilience Will Support Future Upside

Analysts have trimmed the fair value estimate for Merck KGaA from €187.48 to €172.13 as recent price target cuts and more cautious ratings have offset slightly higher revenue growth and profit margin assumptions, along with a lower future P/E multiple. Analyst Commentary Recent research shows a mixed set of opinions on Merck KGaA, but with some clear pockets of optimism that help frame the trimmed fair value estimate.
ナラティブ更新 • Mar 18

MRK: Healthcare Resilience And Limited AI Disruption Will Drive Future Upside

Analysts have trimmed the Merck KGaA fair value estimate from €143.88 to €143.20. This reflects recent cuts to Street price targets in light of a tougher macro backdrop, geopolitical risk and more tempered expectations around sector exposure to AI related disruption.
ナラティブ更新 • Mar 04

MRK: Margin Resilience And New TGCT Therapy Will Shape Future Upside

Analysts have lifted their price target on Merck KGaA to €130 from €125, citing slightly stronger assumptions for revenue growth, profit margins and future P/E, even as recent rating changes across the sector keep overall views balanced. Analyst Commentary Recent research on Merck KGaA reflects a split view, with some firms turning more cautious while others highlight steady execution and valuation support.
ナラティブ更新 • Feb 18

MRK: Margin Gains And HPC Buildout Will Shape Future Upside Potential

Analysts have raised their price target on Merck KGaA to €130 from €125, citing updated expectations for slightly lower revenue growth, a modestly higher discount rate, and a small uplift in projected profit margin and future P/E assumptions. Analyst Commentary Recent research on Merck KGaA presents a mixed picture, but there is a clear cluster of constructive views around valuation, profitability, and execution.
ナラティブ更新 • Feb 03

MRK: Mixed Rating Shifts Will Shape Perceived Balance Of Future Return Potential

Narrative Update: Merck KGaA Analysts have inched their average price target for Merck KGaA up by €5 to €130. This reflects updated views on earnings potential and risk after recent research, including a downgrade at Deutsche Bank and a price target adjustment at Barclays.
ナラティブ更新 • Jan 20

MRK: Refined Earnings Outlook Points To Balanced Future Return Potential

Analysts have lifted their fair value estimate for Merck KGaA to €127 from €105, citing updated assumptions for revenue growth, profit margins and future P/E multiples that are broadly in line with recent Street target moves, such as the new €130 level from Barclays. Analyst Commentary The recent move to a €130 price target from €125 sits broadly in line with the updated fair value estimate of €127, which suggests that expectations are being fine tuned rather than reset.
ナラティブ更新 • Jan 06

MRK: Future Earnings Power And HPC Expansion May Support Upside

Narrative Update on Merck KGaA Analysts have trimmed their price target for Merck KGaA by €20 to €130, citing updated assumptions that reflect a fair value of €184.63, a discount rate of 4.93%, revenue growth of 5.19%, a profit margin of 16.10%, and a future P/E of 23.44x. Analyst Commentary Recent Street research signals that analysts are reassessing Merck KGaA's valuation framework, with the latest work reflecting a price target of €130 compared with a prior level of €150.
ナラティブ更新 • Dec 21

MRK: Future Price Cut Signals Slowing Earnings Momentum Ahead

Analysts have trimmed their price target on Merck KGaA to EUR 130 from EUR 150, reflecting slightly lower long term revenue growth and margin expectations, even as they acknowledge the company's ability to sustain a higher future price to earnings multiple. Analyst Commentary Bearish analysts point to a more challenging backdrop for Merck KGaA, with reduced expectations for long term top line expansion and profitability prompting a reassessment of fair value.
ナラティブ更新 • Dec 07

MRK: Margin Strength And AI Deal Will Drive Future Upside

Analysts have trimmed their price target on Merck KGaA, cutting it by EUR 20 to EUR 130 as they factor in slightly softer long term revenue growth assumptions, even though profit margin expectations have improved modestly. Analyst Commentary Analysts are recalibrating their views on Merck KGaA, with the reduced price target reflecting a more measured stance on the company’s medium to long term prospects while acknowledging an improved profitability outlook.
ナラティブ更新 • Nov 23

MRK: New Leadership Change And AI Partnership Will Drive Shares Higher

Analysts have modestly lowered their price target for Merck KGaA from €150 to €130. They cite a combination of slightly reduced profit margin forecasts and an increased discount rate, even though there is a small uptick in expected revenue growth.
ナラティブ更新 • Nov 03

MRK: Future CEO Appointment Will Support Recovery and Restore Confidence

The analyst price target for Merck KGaA has been reduced from EUR 150 to EUR 130, as analysts cite softer growth expectations and recent earnings disappointments. Analyst Commentary Recent street research reflects a cautious tone among analysts regarding Merck KGaA, with a series of price target reductions and rating adjustments.
ナラティブ更新 • Oct 20

Global Biotechnology And Digital Automation Will Drive Future Healthcare

Analysts have trimmed their fair value estimate for Merck KGaA from €147.53 to €145.94. This change reflects a series of recent price target reductions and persistent concerns regarding growth prospects and limited near-term catalysts.
ナラティブ更新 • Sep 04

Global Biotechnology And Digital Automation Will Drive Future Healthcare

Merck KGaA's consensus price target remains unchanged at €147.53 as analysts adopt a more neutral stance following disappointing Q2 results, lowered guidance, and reduced near-term growth visibility. Analyst Commentary Disappointing Q2 report and weaker-than-expected operational performance.
User avatar
新しいナラティブ • Nov 24

AI-Driven Semiconductor Surge Powers Healthcare And Electronics To New Heights

Strong growth in semiconductor solutions and life sciences boosts Merck's Electronics and Process Solutions sectors, positively impacting future revenue and earnings.

業績と収益の成長予測

XTRA:MRK - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/202823,6753,2693,1305,13013
12/31/202722,4892,9042,8804,79314
12/31/202621,3452,5332,8394,99314
6/30/202621,1352,3702,5784,232N/A
3/31/202620,9562,5322,4194,194N/A
12/31/202521,1022,6082,1453,932N/A
9/30/202521,2712,9572,1023,872N/A
6/30/202521,2192,8631,7993,813N/A
3/31/202521,3162,8182,1844,107N/A
12/31/202421,1562,7772,4204,586N/A
9/30/202420,9632,6962,1604,408N/A
6/30/202420,8702,6262,0524,205N/A
3/31/202420,8202,7221,9613,966N/A
12/31/202320,9932,8241,8973,784N/A
9/30/202321,4282,8931,9123,746N/A
6/30/202322,0613,0782,1984,042N/A
3/31/202322,3273,2422,3344,272N/A
12/31/202222,2323,3262,4914,259N/A
9/30/202221,7853,4732,7884,289N/A
6/30/202220,9523,3112,6584,204N/A
3/31/202220,2543,1882,7344,240N/A
12/31/202119,6873,0553,2344,616N/A
9/30/202119,0722,6893,1254,859N/A
6/30/202118,5462,7333,0734,562N/A
3/31/202117,7952,2782,7024,177N/A
12/31/202017,5341,9872,0023,477N/A
9/30/202017,3171,8841,6842,879N/A
6/30/202016,9241,4191,4982,640N/A
3/31/202016,7761,549N/A2,879N/A
12/31/201916,1521,292N/A2,856N/A
9/30/201915,6581,139N/A2,906N/A
6/30/201915,3541,118N/A2,706N/A
3/31/201915,096938N/A2,332N/A
12/31/201814,8361,071N/A2,219N/A
9/30/201814,5971,921N/A2,120N/A
6/30/201814,3642,218N/A2,147N/A
3/31/201814,3462,389N/A2,299N/A
12/31/201714,5172,548N/A2,696N/A
9/30/201714,6991,787N/A2,842N/A
6/30/201714,9061,628N/A3,152N/A
3/31/201715,0161,529N/A2,943N/A
12/31/201615,0241,629N/A2,518N/A
9/30/201614,6581,480N/A2,449N/A
6/30/201614,0541,387N/A2,253N/A
3/31/201613,4691,418N/A2,268N/A
12/31/201512,8451,109N/A2,195N/A
9/30/201512,3801,269N/A2,618N/A

アナリストによる今後の成長予測

収入対貯蓄率: MRKの予測収益成長率 (年間11.6% ) は 貯蓄率 ( 2.1% ) を上回っています。

収益対市場: MRKの収益 ( 11.6% ) German市場 ( 15.5% ) よりも低い成長が予測されています。

高成長収益: MRKの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: MRKの収益 ( 5.1% ) German市場 ( 6.7% ) よりも低い成長が予測されています。

高い収益成長: MRKの収益 ( 5.1% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: MRKの 自己資本利益率 は、3年後には低くなると予測されています ( 12.7 %)。

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/08/11 04:37
終値2026/08/11 00:00
収益2026/06/30
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Merck KGaA 14 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。42

アナリスト機関
Odile RundquistBaader Helvea Equity Research
Gerhard SchwarzBaader Helvea Equity Research
Charles PitmanBarclays